Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.72 |
| ▸ | RAD52 | P43351 | 3/20 | 0.70 |
| ▸ | DRD2 | P14416 | 3/20 | 0.69 |
| ▸ | DRD1 | P21728 | 3/20 | 0.69 |
| ▸ | HRH1 | P35367 | 3/20 | 0.69 |
| ▸ | DRD3 | P35462 | 3/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.69 |
| ▸ | DRD5 | P21918 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070185 | 0.96 | FPR2 (0.71) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5801554 | 0.95 | FPR2 (0.70) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5802291 | 0.94 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Decanoate SCHEMBL41288 | 0.94 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Decanoate SCHEMBL29563075 | 0.94 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5800312 | 0.94 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5802453 | 0.94 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Enanthate SCHEMBL120793 | 0.94 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5803456 | 0.94 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Enanthate SCHEMBL29389566 | 0.94 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108606-A1 | Conjugated psychotropic drugs and uses thereof | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-05-08 | — | — | US | claimed |
| CN-106659766-B | Enolase 1 (ENO 1) compositions and uses thereof | 博格有限责任公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-112336851-A | Enolase 1(ENO1) compositions and uses thereof | 博格有限责任公司 | 2021-02-09 | — | — | CN | disclosed |
| EP-3293236-B1 | PHASE-CHANGE DIGITAL ADVANCED LITHOGRAPHIC IMAGING INK WITH POLYESTER TRANSFER ADDITIVE | XEROX CORP (US) | 2020-11-11 | — | — | EP | disclosed |
| CN-106102835-B | Enolase 1(ENO1) compositions and uses thereof | 博格有限责任公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-107406445-B | Cyclopropylbenzofuranyl pyridopyrazine diones | 辉瑞公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2019022521-A9 | COMPOSITION FOR DELIVERING PHYSIOLOGICALLY ACTIVE INGREDIENTS INTO BLOOD VESSEL | 주식회사 레모넥스 | 2019-08-15 | — | — | WO | disclosed |
| CN-106478662-B | 5-HT3 receptor antagonist | 武田药品工业株式会社 | 2019-07-02 | — | — | CN | disclosed |
| CN-108524445-A | Medical composition containing poorly water soluble drugs | 兴和株式会社 | 2018-09-14 | — | — | CN | disclosed |
| CN-107530343-A | Triazolylpyridine ketones compound as PDE2 inhibitor | 默沙东公司 | 2018-01-02 | — | — | CN | disclosed |
| EP-1727566-A2 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | Ramot at Tel Aviv University Ltd. (IL) | 2006-12-06 | — | — | EP | disclosed |
| CN-1875021-A | Substituted naphthyridinone derivatives | MERCK & CO INC (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1429844-A4 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | UNIV RAMOT (IL) | 2006-06-07 | — | — | EP | disclosed |
| US-20060111346-A1 | Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same | FAZIX CORPORATION. | 2006-05-25 | — | — | US | disclosed |
| CN-1756551-A | New arylpiperazinyl compounds | PREDIX PHARMACEUTICALS HOLDING (US) | 2006-04-05 | — | — | CN | disclosed |
| WO-2005092392-A2 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-10-06 | — | — | WO | disclosed |
| US-20040242570-A1 | Conjugated psychotropic drugs and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2004-12-02 | — | — | US | disclosed |
| EP-1429844-A2 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003026563-A9 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | UNIV RAMOT (IL) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003026563-A2 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242570-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | FPR2 2983/4885RAD52 4471/4885DRD2 32/4885 |
| US-20060111346-A1 | Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same | HDLBP, LDLR, CETP | FPR2 1313/4885RAD52 2967/4885DRD2 1187/4885 |
| US-20080108606-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | FPR2 2983/4885RAD52 4471/4885DRD2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.